TY - JOUR
T1 - The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy
AU - Bruera, Sebastian
AU - Suarez-Almazor, Maria E.
N1 - Publisher Copyright:
Copyright © 2022 Bruera and Suarez-Almazor.
PY - 2022/8/23
Y1 - 2022/8/23
N2 - The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs). Moderate to severe irAEs are typically treated with glucocorticoids, sometimes with the addition of immunosuppressants as steroid-sparing therapy. However, it is unclear how glucocorticoids and immunosuppressants may impact cancer survival and the efficacy of immune checkpoint therapy on cancer. In this narrative review, we discuss the effects of glucocorticoids and immunosuppressants including methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, tumor-necrosis factor (TNF)-inhibitors, interleukin-6 inhibitors, interleukin-1 inhibitors, abatacept, rituximab, and Janus kinase inhibitors (JAKi) on cancer-specific outcomes in the setting of immune checkpoint inhibitor use.
AB - The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs). Moderate to severe irAEs are typically treated with glucocorticoids, sometimes with the addition of immunosuppressants as steroid-sparing therapy. However, it is unclear how glucocorticoids and immunosuppressants may impact cancer survival and the efficacy of immune checkpoint therapy on cancer. In this narrative review, we discuss the effects of glucocorticoids and immunosuppressants including methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, tumor-necrosis factor (TNF)-inhibitors, interleukin-6 inhibitors, interleukin-1 inhibitors, abatacept, rituximab, and Janus kinase inhibitors (JAKi) on cancer-specific outcomes in the setting of immune checkpoint inhibitor use.
KW - cancer
KW - checkpoint inhibitor therapy
KW - glucocorticoids
KW - immunosuppressants
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85138910079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138910079&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.928390
DO - 10.3389/fonc.2022.928390
M3 - Review article
C2 - 36081549
AN - SCOPUS:85138910079
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 928390
ER -